Literature DB >> 9415401

Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution.

H K Lin1, J M Jez, B P Schlegel, D M Peehl, J A Pachter, T M Penning.   

Abstract

In androgen target tissues, 3alpha-hydroxysteroid dehydrogenase (3alpha-HSD) may regulate occupancy of the androgen receptor (AR) by catalyzing the interconversion of 5alpha-dihydrotestosterone (5alpha-DHT) (a potent androgen) and 3alpha-androstanediol (a weak androgen). In this study, a 3alpha-HSD cDNA (1170 bp) was isolated from a human prostate cDNA library. The human prostatic 3alpha-HSD cDNA encodes a 323-amino acid protein with 69.9%, 84.1%, 99.4%, and 87.9% sequence identity to rat liver 3alpha-HSD and human type 1, type 2, and type 3 3alpha-HSDs, respectively, and is a member of the aldo-keto reductase superfamily. The close homology with human type 2 3alpha-HSD suggests that it is either identical to this enzyme or a structural allele. Surprisingly, when the recombinant protein was expressed and purified from Escherichia coli, the enzyme did not oxidize androsterone when measured spectrophotometrically, an activity previously assigned to recombinant type 2 3alpha-HSD using this assay. Complete kinetic characterization of the purified protein using spectrophotometric, fluorometric, and radiometric assays showed that the catalytic efficiency favored 3alpha-androstanediol oxidation over 5alpha-DHT reduction. Using [14C]-5alpha-DHT as substrate, TLC analysis confirmed that the reaction product was [14C]-3alpha-androstanediol. However, in the reverse reaction, [3H]-3alpha-androstanediol was oxidized first to [3H]-androsterone and then to [3H]-androstanedione, revealing that the expressed protein possessed both 3alpha- and 17beta-HSD activities. The 17beta-HSD activity accounted for the higher catalytic efficiency observed with 3alpha-androstanediol. These findings indicate that, in the prostate, type 2 3alpha-HSD does not interconvert 5alpha-DHT and 3alpha-androstanediol but inactivates 5alpha-DHT through its 3-ketosteroid reductase activity. Levels of 3alpha-HSD mRNA were measured in primary cultures of human prostatic cells and were higher in epithelial cells than stromal cells. In addition, elevated levels of 3alpha-HSD mRNA were observed in epithelial cells derived from benign prostatic hyperplasia and prostate carcinoma tissues. Expression of 3alpha-HSD was not prostate specific, since high levels of mRNA were also found in liver, small intestine, colon, lung, and kidney. This study is the first complete characterization of recombinant type 2 3alpha-HSD demonstrating dual activity and cellular distribution in the human prostate.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9415401     DOI: 10.1210/mend.11.13.0026

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  70 in total

1.  Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3).

Authors:  Adegoke O Adeniji; Barry M Twenter; Michael C Byrns; Yi Jin; Jeffrey D Winkler; Trevor M Penning
Journal:  Bioorg Med Chem Lett       Date:  2011-01-07       Impact factor: 2.823

Review 2.  The syndrome of 17,20 lyase deficiency.

Authors:  Walter L Miller
Journal:  J Clin Endocrinol Metab       Date:  2011-11-09       Impact factor: 5.958

3.  Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships.

Authors:  Adegoke O Adeniji; Barry M Twenter; Michael C Byrns; Yi Jin; Mo Chen; Jeffrey D Winkler; Trevor M Penning
Journal:  J Med Chem       Date:  2012-02-15       Impact factor: 7.446

Review 4.  Intracrinology-revisited and prostate cancer.

Authors:  Trevor M Penning; Andrea J Detlefsen
Journal:  J Steroid Biochem Mol Biol       Date:  2019-10-12       Impact factor: 4.292

5.  Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones.

Authors:  T M Penning; M E Burczynski; J M Jez; C F Hung; H K Lin; H Ma; M Moore; N Palackal; K Ratnam
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

6.  A 3-(4-nitronaphthen-1-yl) amino-benzoate analog as a bifunctional AKR1C3 inhibitor and AR antagonist: Head to head comparison with other advanced AKR1C3 targeted therapeutics.

Authors:  Phumvadee Wangtrakuldee; Adegoke O Adeniji; Tianzhu Zang; Ling Duan; Buddha Khatri; Barry M Twenter; Michelle A Estrada; Tyler F Higgins; Jeffrey D Winkler; Trevor M Penning
Journal:  J Steroid Biochem Mol Biol       Date:  2019-01-11       Impact factor: 4.292

7.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

Review 8.  Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non-gynecological Tissues; Pathology, Physiology, and Drug Discovery.

Authors:  Gonda Konings; Linda Brentjens; Bert Delvoux; Tero Linnanen; Karlijn Cornel; Pasi Koskimies; Marlies Bongers; Roy Kruitwagen; Sofia Xanthoulea; Andrea Romano
Journal:  Front Pharmacol       Date:  2018-09-19       Impact factor: 5.810

Review 9.  Androgen synthesis in adrenarche.

Authors:  Walter L Miller
Journal:  Rev Endocr Metab Disord       Date:  2009-03       Impact factor: 6.514

10.  Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism.

Authors:  Yi Jin; Ling Duan; Seon Hwa Lee; Helenius J Kloosterboer; Ian A Blair; Trevor M Penning
Journal:  J Biol Chem       Date:  2009-02-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.